PYC Therapeutics Ltd (PYC)
Australian Securities Exchange · Australia · prices in AUD · close of 22 Oct 2026
Key indicators
| Last close | AUD 1.810 |
|---|---|
| 52-week range | 1.045 – 2.930 |
| Return, 1 month / 3 months | −37.2% / +12.8% |
| Return, 1 year / 3 years | +48.9% / +225.1% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 32 |
| Volatility (1 year) | 54.3% |
| Worst drawdown (1 year) | -38.8% |
| Average daily value traded | 9.42M AUD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
PYC Therapeutics is an Australian biotechnology company that designs and develops a new class of RNA medicines intended to treat genetic diseases. Its work centres on a delivery technology that carries therapeutic molecules into cells, with early programmes focused on inherited eye conditions that cause vision loss. The company carries out its research and development from its base in Perth, Western Australia, and works on treatments aimed at patients with serious genetic disorders.
PYC Therapeutics Ltd trades under the code PYC on the Australian Securities Exchange in Australia, with its price quoted in Australian dollars (AUD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
PYC Therapeutics Ltd (PYC) trades on the Australian Securities Exchange in Australia. It last closed at AUD 1.810 on 22 October 2026.
Its price-based Market X-Ray is 83 out of 100 (a strong price profile), ranking 62 of 1,816 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 48.9% and over the last three months it rose 12.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Australian Securities Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 81 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 7.5% | ||
| From 52-week high | -37.8% | ||
| Momentum | 91 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 12.8% | ||
| 6-month return | 40.9% | ||
| 12-month return, skipping the last month | 136.9% | ||
| Stability (higher is calmer) | 71 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 54.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -38.8% | ||
| Liquidity | 92 · Strong | Trades actively. | |
| Average daily value traded | 9.42M AUD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | −2.2% |
|---|---|
| 1 month | −37.2% |
| 3 months | +12.8% |
| 6 months | +40.9% |
| 1 year | +48.9% |
| 3 years | +225.1% |
| 5 years | +30.1% |
Signals
| 50-day / 200-day average | 2.344 / 1.683 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.141 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Australian Securities Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.